44 results
424B5
MRK
Merck & Co Inc
10 May 23
Prospectus supplement for primary offering
4:27pm
and life-cycle management, and is expected over time to develop research capabilities in selected therapeutic areas. The Spin-Off is expected
424B5
MRK
Merck & Co Inc
8 May 23
Prospectus supplement for primary offering
8:17am
to be owned and developed within Merck as planned. Organon will have development capabilities initially focused on late-stage development and life-cycle management
424B5
olw4pmr izzxdnfe
9 Dec 21
Prospectus supplement for primary offering
4:37pm
424B5
byn1i3ct18on6slv
7 Dec 21
Prospectus supplement for primary offering
8:13am
S-3ASR
si05ybk
25 Mar 21
Automatic shelf registration
4:46pm
S-3ASR
w76zkc1 6zsdglmk19
25 Mar 21
Automatic shelf registration
4:42pm
424B5
v6nce7 tla0s
18 Jun 20
Prospectus supplement for primary offering
4:59pm
424B5
v7v5spv ipz35fy
16 Jun 20
Prospectus supplement for primary offering
9:04am